Evidence map›Paper›PMID 25555516›Full record

ReviewGrowth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society2015

Effects of growth hormone-releasing hormone on visceral fat, metabolic, and cardiovascular indices in human studies.

Takara L Stanley, Steven K Grinspoon

Open access · greenAbstract readReview
In one paragraph

Review in Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 1 pooled it
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 1 synthesis or guideline pooled it, 58 citations in OpenAlex.

  1. Pooled it
  2. Fibroblast growth factor 21 decreases after liver fat reduction via growth hormone augmentation.Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society · 2017
    Trial
  3. Review
  4. Article
  5. Liver disease in people living with HIV infection: a changing landscape.Nature reviews. Gastroenterology & hepatology · 2026
    Review
  6. Review
  7. Review
  8. Combined antiretroviral therapy with low- or normal-protein, high-calorie diets appears to induce significant deleterious electrocardiographic changes in a rodent model.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas · 2026
    Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Association between obstructive sleep apnea and lipid metabolism during REM and NREM sleep.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2020
    Article
  17. Sarcopenia and fatty liver disease.Hepatology international · 2019
    Review
  18. International journal of molecular sciences · 2019
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Takara L StanleyProgram in Nutritional Metabolism, Neuroendocrine Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Steven K GrinspoonProgram in Nutritional Metabolism, Neuroendocrine Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA. Electronic address: sgrinspoon@partners.org.
Massachusetts General Hospital · US

Funding

HARVARD CLINICAL AND TRANSLATIONAL SCIENCE CENTER (UL1)UL1RR025758 · NCRR · HARVARD MEDICAL SCHOOL · PI NADLER, LEE MARSHALL · 2008 to 2011
$91.4M
ZD6416 Analgesic--Painful Distal Symmetrical PolyneuropaM01RR001066 · NCRR · MASSACHUSETTS GENERAL HOSPITAL · PI BROWN, EMERY N · 1985 to 2008
$37.4M
ROLE OF DIETARY CONSTITUENTS ON GENE EXPRESSION IN INTESTINAL EPITHELIUMP30DK040561 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI CHRISTOPHER P DUGGAN · 1994 to 2026
$31.6M
Physiologic Growth Hormone Effects in HIV LipodystrophyR01DK063639 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI GRINSPOON, STEVEN K. · 2003 to 2012
$4.3M
Consequences and Treatment of Growth Hormone Deficiency in the Metabolic SyndromeR01HL085268 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI GRINSPOON, STEVEN K. · 2007 to 2010
$2.4M
Metabolic Effects of Augmenting Pulsatile Growth Hormone Secretion in HIV-InfectiK23DK089910 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI STANLEY, TAKARA LEAH · 2010 to 2014
$795k
NCRR NIH HHS M01 RR001066NCRR NIH HHS M01RR01066NCRR NIH HHS UL1 RR025758NCRR NIH HHS UL1RR025758NHLBI NIH HHS R01 HL085268NHLBI NIH HHS R01HL85268NIDDK NIH HHS K23 DK089910NIDDK NIH HHS P30 DK040561NIDDK NIH HHS P30 DK40561NIDDK NIH HHS R01 DK063639NIDDK NIH HHS R01DK063639
6 · The paper itself

Abstract

Increased visceral adipose tissue (VAT) is associated with reductions in endogenous GH secretion, possibly as a result of hyperinsulinemia, increased circulating free fatty acid, increased somatostatin tone, and reduced ghrelin. Reduced GH may, in turn, further exacerbate visceral fat accumulation because of decreased hormone-sensitive lipolysis in this depot. Data from multiple populations demonstrate that both reduced GH and increased VAT appear to contribute independently to dyslipidemia, increased systemic inflammation, and increased cardiovascular risk. The reductions in GH in states of visceral adiposity are characterized by reduced basal and pulsatile GH secretion with intact pulse frequency. Treatment with GH-releasing hormone (GHRH) provides a means to reverse these abnormalities, increasing endogenous basal and pulsatile GH secretion without altering pulse frequency. This review describes data from HIV-infected individuals and individuals with general obesity showing that treatment with GHRH significantly reduces visceral fat, ameliorates dyslipidemia, and reduces markers of cardiovascular risk. Further research is needed regarding the long-term efficacy and safety of this treatment modality.

Indexed as

Cardiovascular DiseasesMetabolic DiseasesGrowth Hormone-Releasing HormoneHealth Status IndicatorsHuman Growth HormoneHumansInsulin-Like Growth Factor IIntra-Abdominal FatObesitySignal TransductionGrowth Hormone-Releasing HormoneHuman Growth HormoneInsulin-Like Growth Factor ICardiovascular riskGrowth hormoneGrowth hormone–releasing hormoneObesityVisceral obesity

Identifiers

PMID25555516
PMCPMC4324360
OpenAlexW1965063771

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.